| 2026-06-12 |
复牌提示：
2026-06-11 12:43:17 停牌，复牌日期 2026-06-11 12:48:17
|
| 2026-06-11 |
详情>>
股本变动：
变动后总股本218.85万股
|
| 2026-05-08 |
详情>>
业绩披露：
2026年一季报每股收益-1.48美元,归母净利润-202.24万美元,同比去年增长9.26%
|
| 2026-04-07 |
详情>>
内部人交易：
Claiborne Cary J等共交易5笔
|
| 2026-03-05 |
详情>>
业绩披露：
2025年年报每股收益-11.93美元,归母净利润-797.72万美元,同比去年增长39.56%
|
| 2026-02-03 |
详情>>
拆分方案：
每25.0000合并分成1.0000股
|
| 2026-01-06 |
股东大会：
将于2026-02-26召开股东大会
会议内容 ▼▲
- 1.To approve, pursuant to Nasdaq listing rules, the issuance of up to an aggregate of 13,823,512 shares of our common stock, par value $0.001 per share (“Common Stock”) upon the exercise of our Series F common stock purchase warrants issued in connection with our private placement offering that closed on November 28, 2025, that may be equal to or exceed 20% of our Common Stock outstanding before such offering (the “Warrant Exercise Proposal”);
2.To approve a proposal to adjourn the Special Meeting to a later date, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Warrant Exercise Proposal (the “Adjournment Proposal”).
|
| 2025-11-13 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.45美元,归母净利润-598.1万美元,同比去年增长46.25%
|
| 2025-08-13 |
详情>>
业绩披露：
2025年中报每股收益-0.49美元,归母净利润-418.74万美元,同比去年增长53.13%
|
| 2025-06-27 |
股东大会：
将于2025-08-01召开股东大会
会议内容 ▼▲
- 1.To elect the two (2) nominees for Class I directors named in the accompanying proxy statement to our Board of Directors (the “Board” or “Board of Directors”), each to serve a three-year term expiring at the 2028 annual meeting of stockholders and until such director’s successor is duly elected and qualified;
2.To ratify the appointment of CBIZ CPAs P.C. (f/k/a Marcum, LLP) as our independent registered public accounting firm for our fiscal year ending on December 31, 2025;
3.To approve, pursuant to Nasdaq listing rules, the issuance of up to an aggregate of 6,730,376 shares of our common stock, par value $0.001 per share (“Common Stock”) upon the exercise of our Series B-1 common stock purchase warrants, Series C-1 common stock purchase warrants and placement agent warrants issued in connection with our private placement offering that closed on May 5, 2025, that may be equal to or exceed 20% of our Common Stock outstanding before such offering (the “May Warrant Exercise Proposal”);
4.To approve, pursuant to Nasdaq listing rules, the issuance of up to an aggregate of 19,425,000 shares of Common Stock upon the exercise of our Series D common stock purchase warrants and Series E common stock purchase warrants issued in connection with our offering that closed on June 18, 2025, that may be equal to or exceed 20% of our Common Stock outstanding before such offering (the “June Warrant Exercise Proposal”);
5.To approve an amendment to the Company’s Certificate of Incorporation, as amended, in substantially the form attached to the accompanying proxy statement as Appendix A, to effect a reverse stock split with respect to the Company’s issued and outstanding shares of Common Stock at a ratio of 1-for-2 to 1-for-25 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board and included in a public announcement, subject to the authority of the Board to abandon such amendment (the “Reverse Stock Split Proposal”);
6.To approve an amendment to the Company’s Certificate of Incorporation, as amended, in substantially the form attached to the accompanying proxy statement as Appendix B, at the discretion of our Board, to increase the authorized number of shares of the Company’s Common Stock, from 50,000,000 to 100,000,000 (the “Authorized Increase Proposal”);
7.To approve an amendment to our 2017 Equity Incentive Plan to increase the number of shares of Common Stock that we will have authority to grant under the plan from 2,000,000 to 5,000,000 (the “Plan Increase Proposal”);
8.To approve a proposal to adjourn the 2025 Annual Meeting to a later date, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Reverse Stock Split Proposal, the Authorized Increase Proposal, the May Warrant Exercise Proposal and/or the June Warrant Exercise Proposal (the “Adjournment Proposal”);
9.To transact such other business as may properly come before the meeting or any adjournments or postponements of the meeting.
|
| 2025-06-10 |
股东大会：
将于2025-07-24召开股东大会
会议内容 ▼▲
- 1.To elect the two nominees for Class I directors named in the accompanying proxy statement to our Board of Directors (the “Board” or “Board of Directors”), each to serve a three-year term expiring at the 2028 annual meeting of stockholders and until such director’s successor is duly elected and qualified;
2.To ratify the appointment of CBIZ CPAs P.C. (f/k/a Marcum, LLP) (“CBIZ”) as our independent registered public accounting firm for our fiscal year ending on December 31, 2025;
3.To approve, pursuant to Nasdaq listing rules, the issuance of up to an aggregate of 6,730,376 shares of our common stock upon the exercise of our Series B-1 common stock purchase warrants, Series C-1 common stock purchase warrants and placement agent warrants issued in connection with our private placement offering that closed on May 5, 2025, that may be equal to or exceed 20% of our Common Stock outstanding before such offering (the “Warrant Exercise Proposal”);
4.To approve an amendment to the Company’s Certificate of Incorporation, as amended, in substantially the form attached to the accompanying proxy statement as Appendix A, at the discretion of our Board of Directors, to effect a reverse stock split with respect to the Company’s issued and outstanding shares of Common Stock, including stock held by the Company as treasury shares, at a ratio of 1-for-2 to 1-for-25 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board and included in a public announcement, subject to the authority of the Board of Directors to abandon such amendment (the “Reverse Stock Split Proposal”);
5.To approve a proposal to adjourn the 2025 Annual Meeting to a later date, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Reverse Stock Split Proposal and/or the Warrant Exercise Proposal (the “Adjournment Proposal”);
6.To transact such other business as may properly come before the meeting or any adjournments or postponements of the meeting.
|
| 2025-05-14 |
详情>>
业绩披露：
2025年一季报每股收益-0.34美元,归母净利润-222.88万美元,同比去年增长65.59%
|
| 2025-03-04 |
详情>>
业绩披露：
2024年年报每股收益-2.72美元,归母净利润-1319.75万美元,同比去年增长-157.59%
|
| 2024-11-13 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-2.57美元,归母净利润-1112.67万美元,同比去年增长-247.38%
|
| 2024-09-27 |
股东大会：
将于2024-11-12召开股东大会
会议内容 ▼▲
- 1.To elect the two nominees for Class III directors named in the accompanying proxy statement to our Board of Directors (the “Board” or “Board of Directors”), each to serve a three-year term expiring at the 2027 annual meeting of stockholders and until such director’s successor is duly elected and qualified;
2.To ratify the appointment of Marcum LLP as our independent registered public accounting firm for our fiscal year ending on December 31, 2024;
3.To approve an amendment to our 2017 Equity Incentive Plan to increase the number of shares of common stock that we will have authority to grant under the plan from 500,000 to 2,000,000;
4.To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in this proxy statement;
5.To approve, on an advisory basis, a frequency for holding an advisory vote on executive compensation;
6.To transact such other business as may properly come before the meeting or any adjournments or postponements of the meeting.
|
| 2024-08-13 |
详情>>
业绩披露：
2024年中报每股收益-2.5美元,归母净利润-893.49万美元,同比去年增长-391.46%
|
| 2024-05-14 |
详情>>
业绩披露：
2024年一季报每股收益-2.19美元,归母净利润-647.66万美元,同比去年增长-122.88%
|
| 2024-04-01 |
详情>>
业绩披露：
2023年年报每股收益-3.6美元,归母净利润-512.33万美元,同比去年增长59.76%
|
| 2023-12-08 |
股东大会：
将于2024-01-11召开股东大会
会议内容 ▼▲
- 1.The approval, pursuant to Nasdaq listing rules, of the issuance of up to an aggregate of 3,007,092 shares of our common stock upon the exercise of our common stock purchase warrants issued or issuable to an institutional investor and designees of the placement agent in connection with our private placement offering that closed on October 24, 2023 that may be equal to or exceed 20% of our common stock outstanding before such offering (the “Warrant Exercise Proposal”);
2.The approval of a proposal to adjourn the Special Meeting to a later date, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Warrant Exercise Proposal.
|
| 2023-10-02 |
股东大会：
将于2023-11-02召开股东大会
会议内容 ▼▲
- 1.To elect the two (2) nominees for Class II directors named in the accompanying proxy statement to our Board of Directors (the “Board” or “Board of Directors”), each to serve a three-year term expiring at the 2026 annual meeting of stockholders and until such director’s successor is duly elected and qualified;
2.To ratify the appointment of Marcum LLP as our independent registered public accounting firm for our fiscal year ending on December 31, 2023;
3.To approve an amendment to our 2017 Equity Incentive Plan to increase the number of shares of common stock that we will have authority to grant under the plan (as adjusted to reflect the recent stock 1:25 reverse stock split that we effected on August 4, 2023) from 380,000 to 500,000;
4.To transact such other business as may properly come before the meeting or any adjournments or postponements of the meeting.
|
| 2023-08-07 |
详情>>
拆分方案：
每25.0000合并分成1.0000股
|
| 2023-03-06 |
股东大会：
将于2023-04-12召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Company’s Certificate of Incorporation (the “Charter”), in substantially the form attached to the proxy statement as Annex A, to, at the discretion of the Board of Directors of the Company (the “Board”), effect a reverse stock split with respect to the Company’s issued and outstanding common stock, par value $0.001 per share (“Common Stock”), including stock held by the Company as treasury shares, at a ratio of 1-for-2 to 1-for-50 (the “Range”), with the ratio within such Range (the “Reverse Stock Split Ratio”) to be determined at the discretion of the Board (the “Reverse Stock Split Proposal”) and included in a public announcement;
2.To approve an adjournment of the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event there are not sufficient votes in favor of the Reverse Stock Split Proposal (the “Adjournment Proposal”).
|
| 2022-09-01 |
股东大会：
将于2022-10-13召开股东大会
会议内容 ▼▲
- 1.To elect the two (2) nominees for Class I directors named in the accompanying proxy statement to our Board of Directors (the “Board” or “Board of Directors”), each to serve a three-year term expiring at the 2025 annual meeting of stockholders and until such director’s successor is duly elected and qualified;
2.To ratify the appointment of Friedman LLP (which will merge with Marcum LLP effective September 1, 2022) as our independent registered public accounting firm for our fiscal year ending on December 31, 2022;
3.To approve an amendment to our 2017 Equity Incentive Plan to increase the number of shares of common stock that we will have authority to grant under the plan from 7,500,000 to 9,500,000;
4.To transact such other business as may properly come before the meeting or any adjournments or postponements of the meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-23 |
股东大会：
将于2021-09-27召开股东大会
会议内容 ▼▲
- (1)to elect the two (2) nominees for Class III directors named herein to our Board of Directors (the “Board” or “Board of Directors”), each to serve a three-year term expiring at the 2024 annual meeting of stockholders and until such director’s successor is duly elected and qualified;
(2)to ratify the appointment of Friedman LLP as our independent registered public accounting firm for our fiscal year ending on December 31, 2021;
(3)to approve an amendment to our 2017 Equity Incentive Plan to increase the number of shares of common stock that we will have authority to grant under the plan from 5,500,000 to 7,500,000;
(4)to transact such other business as may properly come before the meeting or any adjournments or postponements of the meeting.
|
| 2020-07-21 |
股东大会：
将于2020-09-01召开股东大会
会议内容 ▼▲
- 1.to elect the two (2) nominees for Class II directors named herein to our Board of Directors (the “Board” or “Board of Directors”), each to serve a three-year term expiring at the 2023 annual meeting of stockholders and until such director’s successor is duly elected and qualified;
2.to ratify the appointment of Friedman LLP as our independent registered public accounting firm for our fiscal year ending on December 31, 2020;
3.to approve an amendment to our 2017 Equity Incentive Plan to increase the number of shares of common stock that we will have authority to grant under the plan from 3,500,000 to 5,500,000;
4.to transact such other business as may properly come before the meeting or any adjournments or postponements of the meeting.
|
| 2019-07-08 |
股东大会：
将于2019-08-16召开股东大会
会议内容 ▼▲
- 1.to elect the two (2) nominees for Class I directors named herein to our Board of Directors (the “Board” or “Board of Directors”), each to serve a three-year term expiring at the 2022 annual meeting of stockholders and until such director’s successor is duly elected and qualified;
2.to ratify the appointment of Friedman LLP as our independent registered public accounting firm for our fiscal year ending on December 31, 2019;
3.to approve an amendment to our 2017 Equity Incentive Plan to increase the number of shares of common stock that we will have authority to grant under the plan from 1,750,000 to 3,500,000;
4.to transact such other business as may properly come before the meeting or any adjournments or postponements of the meeting.
|